119 related articles for article (PubMed ID: 18212177)
1. Interferon-alpha in oncology patients: fewer psychiatric side effects than anticipated.
Bannink M; Kruit WH; Van Gool AR; Sleijfer S; van der Holt B; Eggermont AM; Stoter G; Hengeveld MW
Psychosomatics; 2008; 49(1):56-63. PubMed ID: 18212177
[TBL] [Abstract][Full Text] [Related]
2. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy.
Capuron L; Ravaud A; Miller AH; Dantzer R
Brain Behav Immun; 2004 May; 18(3):205-13. PubMed ID: 15050647
[TBL] [Abstract][Full Text] [Related]
3. Interferon-α as an appropriate model of substance-induced depression.
Galvão-de Almeida A; Miranda-Scippa A; De Oliveira IR; Quarantini L
Psychosomatics; 2011; 52(1):95. PubMed ID: 21300205
[No Abstract] [Full Text] [Related]
4. Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon-alpha treatment in patients with malignant melanoma: results from the multicenter DeCOG trial.
Heinze S; Egberts F; Rötzer S; Volkenandt M; Tilgen W; Linse R; Boettjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Hinzpeter A; Hauschild A; Schaefer M
J Immunother; 2010 Jan; 33(1):106-14. PubMed ID: 19952950
[TBL] [Abstract][Full Text] [Related]
5. Safety of pegylated interferon-alpha-2a in adjuvant therapy of intermediate and high-risk melanomas.
Loquai C; Nashan D; Hensen P; Luger TA; Grabbe S; Sunderkötter C; Schiller M
Eur J Dermatol; 2008; 18(1):29-35. PubMed ID: 18086586
[TBL] [Abstract][Full Text] [Related]
6. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
Alatrash G; Hutson TE; Molto L; Richmond A; Nemec C; Mekhail T; Elson P; Tannenbaum C; Olencki T; Finke J; Bukowski RM
J Clin Oncol; 2004 Jul; 22(14):2891-900. PubMed ID: 15254058
[TBL] [Abstract][Full Text] [Related]
7. Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferon-alpha: course and relationship with psychiatric status.
Van Gool AR; Verkerk R; Fekkes D; Bannink M; Sleijfer S; Kruit WH; van der Holt B; Scharpé S; Eggermont AM; Stoter G; Hengeveld MW
Psychiatry Clin Neurosci; 2008 Oct; 62(5):597-602. PubMed ID: 18950381
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma.
Friebe A; Schwarz MJ; Schmid-Wendtner M; Volkenandt M; Schmidt F; Horn M; Janssen G; Schaefer M
J Immunother; 2007 Apr; 30(3):333-7. PubMed ID: 17414324
[TBL] [Abstract][Full Text] [Related]
9. Depression in hospitalized patients with malignant melanoma treated with interferon-alpha-2b: primary to induced disorders.
Navinés R; Gómez-Gil E; Puig S; Baeza I; De Pablo J; Martín-Santos R
Eur J Dermatol; 2009; 19(6):611-5. PubMed ID: 19709980
[TBL] [Abstract][Full Text] [Related]
10. Incidence of psychiatric side effects during pegylated interferon- alpha retreatment in nonresponder hepatitis C virus-infected patients.
Quarantini LC; Bressan RA; Galvão A; Batista-Neves S; Paraná R; Miranda-Scippa A
Liver Int; 2007 Oct; 27(8):1098-102. PubMed ID: 17845538
[TBL] [Abstract][Full Text] [Related]
11. [Depression during interferon therapy in renal cell cancer patients--comparison with chronic hepatitis C patients].
Sakamoto H; Inoue K; Shimada M; Yoshida H; Otsubo T; Miyaoka H; Kamizima K; Ishii M; Mitamura K
Nihon Hinyokika Gakkai Zasshi; 2000 Sep; 91(9):611-7. PubMed ID: 11068424
[TBL] [Abstract][Full Text] [Related]
12. Subthreshold mania as predictor of depression during interferon treatment in HCV+ patients without current or lifetime psychiatric disorders.
Dell'Osso L; Pini S; Maggi L; Rucci P; Del Debbio A; Carlini M; Baldini A; Ferrari G; Manca E; Beverini E; Amore M; Scarallo V; Semeraro Q; Brunetto M; Bonino F; Maj M
J Psychosom Res; 2007 Mar; 62(3):349-55. PubMed ID: 17324686
[TBL] [Abstract][Full Text] [Related]
13. [Alpha-interferon and mental disorders].
Debien C; De Chouly De Lenclave MB; Foutrein P; Bailly D
Encephale; 2001; 27(4):308-17. PubMed ID: 11686052
[TBL] [Abstract][Full Text] [Related]
14. Narcoleptic-like Episodes in a Patient Receiving Pegylated Interferon-alpha 2b: A Case Report and Review of Literature.
Lawson BO; Khong HT
Anticancer Res; 2017 Mar; 37(3):1365-1368. PubMed ID: 28314304
[TBL] [Abstract][Full Text] [Related]
15. Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy.
Capuron L; Ravaud A; Dantzer R
J Clin Oncol; 2000 May; 18(10):2143-51. PubMed ID: 10811680
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous administration of interferon alpha and gamma in patients with metastatic renal cell carcinoma.
Koga S; Nishikido M; Matsuya F; Kanetake H; Saito Y
Anticancer Res; 1999; 19(6C):5547-50. PubMed ID: 10697614
[TBL] [Abstract][Full Text] [Related]
17. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C.
Schaefer M; Schwaiger M; Garkisch AS; Pich M; Hinzpeter A; Uebelhack R; Heinz A; van Boemmel F; Berg T
J Hepatol; 2005 Jun; 42(6):793-8. PubMed ID: 15885349
[TBL] [Abstract][Full Text] [Related]
18. Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma.
Daud A; Soon C; Dummer R; Eggermont AM; Hwu WJ; Grob JJ; Garbe C; Hauschild A
Expert Opin Biol Ther; 2012 Aug; 12(8):1087-99. PubMed ID: 22694288
[TBL] [Abstract][Full Text] [Related]
19. Low-dose recombinant IL-2 induces psychological changes: monitoring by Minnesota Multiphasic Personality Inventory (MMPI).
Pizzi C; Caraglia M; Cianciulli M; Fabbrocini A; Libroia A; Matano E; Contegiacomo A; Del Prete S; Abbruzzese A; Martignetti A; Tagliaferri P; Bianco AR
Anticancer Res; 2002; 22(2A):727-32. PubMed ID: 12014643
[TBL] [Abstract][Full Text] [Related]
20. Major depression and risk of depressive symptomatology associated with short-term and low-dose interferon-alpha treatment.
Beratis S; Katrivanou A; Georgiou S; Monastirli A; Pasmatzi E; Gourzis P; Tsambaos D
J Psychosom Res; 2005 Jan; 58(1):15-8. PubMed ID: 15771865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
